News & Updates
Filter by Specialty:

Cefoperazone-sulbactam superior to piperacillin-tazobactam for severe CAP
Treatment with cefoperazone-sulbactam demonstrates similar efficacy to that of piperacillin-tazobactam in adult patients with severe community-acquired pneumonia (SCAP), according to a study. However, after adjusting for disease severity, cefoperazone-sulbactam appears superior to piperacillin-tazobactam.
Cefoperazone-sulbactam superior to piperacillin-tazobactam for severe CAP
21 Sep 2023
Budesonide falls short of improving hyposmia related to COVID-19
Local intranasal treatment with budesonide does not appear to be effective for persistent hyposmia in patients with nonsevere COVID-19, according to a study.
Budesonide falls short of improving hyposmia related to COVID-19
21 Sep 2023
Unique interventional pulmonology book highlights diagnostic, therapeutic case studies
Dr Jamalul Azizi Abdul Rahaman, a consultant pulmonologist (respiratory physician) at Sultan Idris Shah Serdang Hospital, and Dr Tinku Joseph, chief of Interventional Pulmonology at Amrita Institute of Medical Sciences in India, edited a book titled “A Case-Based Approach to Interventional Pulmonology: A Focus on Asian Perspectives.” The book was launched in conjunction with the 9th Asian Pacific Congress on Bronchology and Interventional Pulmonology, held at Le Meridien Hotel, Putrajaya, in May 2023. Here, they provide a summary of the book and answer questions posed by MIMS Doctor.
Unique interventional pulmonology book highlights diagnostic, therapeutic case studies
20 Sep 2023
Sleep problems tied to risk of COVID-19 outcomes
A cross-sectional analysis has found an association between insomnia, poor sleep quality, and extremes of sleep duration and increased COVID-19 infection and hospitalization.
Sleep problems tied to risk of COVID-19 outcomes
18 Sep 2023
Durvalumab plus radiotherapy shows promise in unresectable NSCLC
In the treatment of patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, and locally advanced nonsmall cell lung cancer (NSCLC), the use of durvalumab immunotherapy in combination with curative radiotherapy yields survival gains with tolerable adverse events (AEs), as shown in the results of the phase II DOLPHIN trial.